Ultragenyx Pharmaceutical (RARE) Interest & Investment Income (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Interest & Investment Income data on file, last reported at $6.0 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income fell 14.29% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $24.2 million, a 31.29% decrease from a year earlier, with the FY2025 full-year figure at $25.0 million, down 32.43% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $6.0 million, down from $6.5 million in the prior quarter.
• Over the last five years, Interest & Investment Income for RARE reached as high as $10.7 million in Q3 2024 and fell as low as $494000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $6.2 million across 5 years, with a median of $6.2 million in 2022.
• Across the five-year window, Interest & Investment Income surged 1308.64% in 2022 and sank 45.36% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $6.2 million in 2022, then surged by 43.03% to $8.9 million in 2023, then climbed by 13.3% to $10.0 million in 2024, then plunged by 35.17% to $6.5 million in 2025, then dropped by 7.86% to $6.0 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $6.0 million in Q1 2026, $6.5 million in Q4 2025, and $5.9 million in Q3 2025.